1-2 of 2
F. Crippa, MD
Close
Sort by
Journal Articles

Infusions of HSV-TK Engineered Donor Lymphocytes Effectively Protect Patients Undergoing Haploidentical Stem Cells Trasplantation (HSCT) from Infectious Mortality.

M.T. Lupo Stanghellini, MD, C. Bonini, MD, E. Provasi, BSC, M. Bernardi, MD, J. Peccatori, MD, A. Bondanza, MD, Z. Magnani, PhD, S.K. Perna, MD, F. Crippa, MD, V. Valtolina, PhD, M. Salomoni, PhD, L. Turchetto, PhD, S. Toma, PhD, C. Traversari, PhD, S. Colombi, PhD, C. Gallo Stampino, MD, P. Bruzzi, MD, L. Castagna, MD, J. Apperley, MD, S. Slavin, MD, F. Ciceri, MD, Claudio Bordignon, MD
Journal: Blood
Blood (2007) 110 (11): 1056.
https://doi.org/10.1182/blood.V110.11.1056.1056
Published: 2007
Journal Articles

HSV-TK Engineered Donor Lymphocytes Add-Backs Reduce Late Mortality and Improve Survival of High Risk Acute Leukemia after Haplo-HSCT: Results of a Phase II Multicenter Trial.

F. Ciceri, MD, C. Bonini, MD, M.T. Lupo Stanghellini, MD, A. Bondanza, MD, Z. Magnani, PhD, S. Perna, MD, M. Bernardi, MD, J. Peccatori, MD, A. Pescarollo, MD, P. Servida, MD, F. Crippa, MD, L. Callegaro, RN, M. Salomoni, PhD, L. Turchetto, PhD, S. Toma, PhD, P. Bruzzi, MD, L. Castagna, MD, A. Santoro, MD, J. Apperley, MD, S. Slavin, MD, S. Colombi, PhD, C. Gallo Stampino, MD, M. Bregni, MD, C. Bordignon, MD
Journal: Blood
Blood (2005) 106 (11): 439.
https://doi.org/10.1182/blood.V106.11.439.439
Published: 2005